CheckMate 577 是一项随机、双盲、III 期研究,共纳入 794 例新辅助放化疗后有残留病灶且接受 R0 切除的 II 或 III 期食管或胃食管交界癌患者,以 2:1 比例随机接受纳武利尤单抗(240 mg/2 周,共 16 周,此后剂量为 480 mg/4 周)或...
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary.
Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma.
Checkmate 577–adjuvant treatment of esophageal or gastroesophageal junction cancer; Checkmate 238–adjuvant treatment of patients with completely resected Stage III or Stage IV melanoma; Checkmate 76K–adjuvant treatment of patients 12 years of age and older with completely resected Stage IIB or Stage ...
Line range hint 577-586: Yo, these comments are crying for help! Let's get them some assistance! 🆘 The "FE team HELP!" comments indicate unresolved styling issues with the Stack component's layout. This could be improved using CSS Grid or Flexbox properly. Would you like me to help...
Update monitors page Autocomplete field to use inputValue prop instea… … a798f98 refactor logger for clarity c9ba0be Merge pull request #861 from bluewave-labs/feat/maintenance-page … 5001c5c Merge pull request #917 from bluewave-labs/master … 82de7ed Merge branch 'develop'...
CheckMate 577 是一项随机、双盲、III 期研究,共纳入 794 例新辅助放化疗后有残留病灶且接受 R0 切除的 II 或 III 期食管或胃食管交界癌患者,以 2:1 比例随机接受纳武利尤单抗(240 mg/2 周,共 16 周,此后剂量为 480 mg/4 周)或安慰剂治疗,辅助治疗最多持续 1 年,主要终点为 DFS(无病生存期)。
CheckMate 577 是一项随机、双盲、III 期研究,共纳入 794 例新辅助放化疗后有残留病灶且接受 R0 切除的 II 或 III 期食管或胃食管交界癌患者,以 2:1 比例随机接受纳武利尤单抗(240 mg/2 周,共 16 周,此后剂量为 480 mg/4 周)或安慰剂治疗,辅助治疗最多持续 1 年,主要终点为 DFS(无病生存期)。